Catalyst Wire Dossier Catalyst Wire Dossier

ACT-541468 (Daridorexant)

daridorexant · Idorsia Pharmaceuticals Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ACT-541468 (Daridorexant), covering 2022-03-02 to 2022-03-25. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep [Phase 3]

See pricing